Late-Breaking Data

Positive Topline Data from HERIZON-BTC-01: Zanidatamab in Previously Treated HER2-Amplified BTC

December 2022, Vol 3, No 4 — December 22, 2022

Although HER2 alterations have been reported in up to 20% of biliary tract cancers (BTCs), no HER2-targeted therapies are currently approved for the treatment of BTC.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

CCA News Print Edition

CCA News Weekly e‑Newsletter

I have reviewed and consent to the terms of CCA News's Privacy Policy, and CCA News has my permission to retain my information in its database, and to forward pertinent communications to me.

Late-Breaking Data

Subscribe Today!

I'd like to receive:

Stay In The Know